25 completed, 10 unknown, 4 terminated, 2 no longer available. 18 Phase 2, 11 Not applicable, 10 Phase 3, 7 Phase 1, 5 Early Phase 1.
Follow COVID-19 Serotherapy: new trials by email Literature Review of COVID-19 Serotherapy trials Research Report on COVID-19 Serotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Cold Plasma in Chronic Wound Healing Cold Atmospheric Plasma treatment - Chronic Wounds, Venous Leg Ulcer (VLU) | Not applicable | Not yet recruiting | Plasana Medical | 66 | 2025-06-01 | 2025-05-09 |
| A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation COVID Convalescent Plasma - COVID-19, Hematopoietic Stem Cell Transplantation | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 72 | 2023-06-10 | 2023-06-15 |
| Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19 SARS-CoV-2 convalescent plasma - Covid19, Immuno-Deficiency | Phase 3 | Unknown | University Hospital, Geneva | 100 | 2021-04-08 | 2021-04-08 |
| Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) COVID-19 convalescent plasma - Severe COVID-19 | Phase 2 | Unknown | University of Erlangen-Nürnberg Medical School | 58 | 2021-01-18 | 2021-01-20 |
| Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness COVID-19 convalescent plasma treatment - COVID-19 Convalescent Plasma Treatment | Not applicable | Terminated | Wroclaw Medical University | 396 | 2020-12-22 | 2022-04-05 |
| Convalescent Plasma for Treatment of COVID-19 SARS-CoV-2 convalescent plasma, Standard of care - Covid19 | Phase 2 / Phase 3 | Completed | Joakim Dillner | 59 | 2020-12-03 | 2022-02-09 |
| Convalescent Plasma as Adjunct Therapy for COVID-19 Convalescent plasma treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | National Institute of Health Research and Development, Ministry of Health Republic of Indonesia | 364 | 2020-12-01 | 2021-06-02 |
| Early Use of Hyperimmune Plasma in COVID-19 hyperimmune plasma - Covid19 | Not applicable | Unknown | Catherine Klersy | 260 | 2020-11-19 | 2022-03-31 |
| VA CoronavirUs Research and Efficacy Studies-1 Convalescent Plasma, Masked Saline Placebo - COVID-19 | Phase 3 | Terminated | VA Office of Research and Development | 75 | 2020-11-16 | 2022-09-23 |
| Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. COVID-19 convalescent plasma, Anti-COVID-19 human immunoglobulin, Standard (specific) therapy for COVID-19 - Coronavirus Disease 2019 (COVID-19) | Phase 2 / Phase 3 | Unknown | Lifefactors Zona Franca, SAS | 75 | 2020-09-01 | 2020-07-10 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study Plasma, Standard Therapy - Coronavirus, Coronavirus Infection | Phase 2 / Phase 3 | Completed | Universidad del Rosario | 92 | 2020-08-08 | 2020-11-27 |
| Convalescent Plasma for COVID-19 Patients Convalescent COVID 19 Plasma - COVID 19 | Early Phase 1 | Completed | Vinmec Research Institute of Stem Cell and Gene Technology | 4 | 2020-08-01 | 2024-06-06 |
| ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) COVID-19 convalescent plasma - COVID-19, Severe Acute Respiratory Syndrome (SARS) | Phase 2 | Terminated | Corewell Health East | 71 | 2020-07-16 | 2022-03-09 |
| Hyperimmune Plasma for Patients With COVID-19 treated with hyperimmune plasma - Covid19 | Not applicable | Unknown | ANNA FALANGA | 100 | 2020-07-02 | 2020-11-03 |
| Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 SARS-CoV-2 convalescent plasma treatment, Standard care - Sars-CoV2, Covid-19 | Phase 2 / Phase 3 | Unknown | Fundación Santa Fe de Bogota | 236 | 2020-07-01 | 2020-06-11 |
| Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure Multiple Doses of Anti-SARS-CoV-2 convalescent plasma - Covid-19, Sars-CoV2 | Early Phase 1 | Terminated | Noah Merin | 6 | 2020-06-27 | 2021-11-08 |
| Assessment of Safety and Efficacy of CCP COVID Convalescent Plasma - Covid19 | Not applicable | Completed | Makerere University | 136 | 2020-06-16 | 2021-01-15 |
| Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients COVID-19 Convalescent Plasma (CCP), Placebo - COVID-19, Sars-CoV2 | Phase 2 | Completed | Priscilla Hsue, MD | 34 | 2020-06-09 | 2022-10-07 |
| Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19 Multiple doses of anti-SARS-CoV-2 Convalescent Plasma - COVID-19 | Early Phase 1 | Completed | Hospital Regional Dr. Rafael Estévez | 30 | 2020-06-06 | 2022-10-27 |
| Convalescent Plasma to Limit SARS-CoV-2 Associated Complications SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor - SARS-CoV 2 | Phase 2 | Completed | Johns Hopkins University | 1225 | 2020-06-03 | 2023-06-02 |
Showing 20 of 44. Sign in to see all of them.
COVID-19 (35) · Coronavirus Infections (7) · Severe Acute Respiratory Syndrome (4) · Critical Illness (1) · Dental Caries (1) · Diabetic Foot (1) · Frailty (1) · Hemorrhagic Fever, Ebola (1) · Lymphoma, Follicular (1) · Onychomycosis (1) · Pneumonia (1) · Pressure Ulcer (1) · Respiratory Insufficiency (1) · Varicose Ulcer (1) · Viremia (1)
Joakim Dillner (3) · Universidad del Rosario (2) · University of Pennsylvania (2) · VA Office of Research and Development (2) · ANNA FALANGA (1) · Andalusian Network for Design and Translation of Advanced Therapies (1) · Catherine Klersy (1) · Clinical Research Management, Inc. (1) · Corewell Health East (1) · DeviceFarm, Inc. (1) · Federal Research Clinical Center of Federal Medical & Biological Agency, Russia (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fundación Santa Fe de Bogota (1) · Gailen D. Marshall Jr., MD PhD (1)
United States (18) · Italy (5) · Colombia (4) · Sweden (3) · Argentina (1) · Chile (1) · China (1) · Germany (1) · Indonesia (1) · Liberia (1) · Panama (1) · Poland (1) · Puerto Rico (1) · Russia (1) · Spain (1)
Johan Ursing, MD, PhD (2) · Juan M Anaya Cabrera, MD, PhD (2) · Alexander V Averyanov, MD, PhD (1) · Annie Leutkemeyer, MD (1) · Carsten Willam, MD (1) · Cesare Perotti, MD (1) · David H Muljono, MD, PhD. (1) · David Hager, MD PhD (1) · David J Sullivan, MD (1) · Dean J Kereiakes, MD (1) · Debra J Levan, DO (1) · Dured Dardari, MD, PhD (1) · Edward N. Janoff, MD (1) · Enos Bernasconi, MD (1) · Eric Salazar, MD, PhD (1)
PMID 34013969, PMID 36734509, PMID 37162745, PMID 25030060, PMID 32648959, PMID 33044747, PMID 12777656, PMID 15214887, PMID 15616839, PMID 16211552, PMID 16940336, PMID 25469648, PMID 26618098, PMID 27959686, PMID 29659889, PMID 32129478, PMID 32253318, PMID 32468508, PMID 32525844, PMID 32817978, PMID 33092632, PMID 33232588, PMID 33523609, PMID 33604400, PMID 33657114, PMID 34153099, PMID 34293119, PMID 34376401, PMID 34381030, PMID 34788233, PMID 34880010, PMID 34928960, PMID 34981068, PMID 35229691, PMID 35353960, PMID 35439166, PMID 35761219, PMID 36351430, PMID 36722044, PMID 37131659, PMID 37560085, PMID 38483534, PMID 40400480, PMID 40630565, PMID 41394817, PMID 41446701
R01AI152078 (1), R44DE019041 (1), U24TR001609 (1), UL1TR003098 (1)